Introduction/Background To evaluate the potential role of interlukin-31 and interlukin-33 in prognosis from endometrial cancer.

Methodology Tissue and serum samples and clinical data were collected from 260 patients with endometrial cancer and 150 control patients with benign uterine diseases. The expressions of interlukin-31 and interlukin-33 and their receptors were quantified by immunohistochemistry and ELISA testing. After surgery, all patients were followed up for an average of 56.3 months. Surgical effects were evaluated based on the patients‘ symptoms and signs. A two-sided P value <0.05 was considered significant.

Results IL-31, IL-33 and their receptors were significantly accumulated with the progression of endometial cancer, in comparison to the controls. Moreover, the expressions were correlated with clinical characteristics, including tumor stage, differentiation and associated with patients‘ disease-free survival.

Conclusion Limited data were available between the expressions of IL-31 and IL-33 in patients with endometrial cancer. Our study findings suggested that the expressions of IL-31 and IL-33 might become possible biomarkers for the diagnosis and prediction in endometrial cancer.

Disclosure This work was supported by the National Natural Science Foundation of China (no. 81572573).